公开(公告)号：KR1020120022699A

公开(公告)日：2012-03-12

申请号：KR1020117016361

申请日：2009-12-11

Applicant: 한국과학기술원 ,  고규영

Inventor： 고규영 ,  정기훈 ,  고영준 ,  김선창

IPC: C07K19/00 ,  C12N15/62 ,  A61K38/17 ,  A61P35/00

CPC classification number: C07K16/241 ,  C07K14/71 ,  C07K14/715 ,  C07K16/22 ,  C07K2317/31 ,  C07K2319/70

Abstract: PURPOSE: A fusion protein which simultaneously binds to VEGF and TNF-alpha is provided to treat symptom and diseases of VEGF-A and TNF-alpha. CONSTITUTION: A fusion protein is able to bind to TNFR2 which is operatively linked to polymerization ingredients, VEGF polypeptide containing VEGF polypeptides, and TNF polypeptide. The NFR2 ingredient contains amino acid sequences of cysteine rich domain 1, cysteine-rich domain 2, cysteine-rich domain 3, or cysteine-rich domain 4. The polymerization ingredients contain an immunoglobulin domain. The immunoglobulin domain is Fc domain of IgG, heavy chain of IgG, or light chain of IgG. A composition contains fusion polypeptides and pharmaceutically acceptable carrier.

Abstract translation: 目的：提供同时与VEGF和TNF-α结合的融合蛋白，以治疗VEGF-A和TNF-α的症状和疾病。 构成：融合蛋白能够结合TNFR2，TNFR2可操作地连接到聚合成分，含有VEGF多肽的VEGF多肽和TNF多肽。 NFR2成分含有富含半胱氨酸的结构域1，富含半胱氨酸的结构域2，富含半胱氨酸的结构域3或富含半胱氨酸的结构域4的氨基酸序列。聚合成分含有免疫球蛋白结构域。 免疫球蛋白结构域是IgG的Fc结构域，IgG的重链或IgG的轻链。 组合物含有融合多肽和药学上可接受的载体。